Be careful! This behavior of pharmaceutical companies will lead to the loss of market

[trends of pharmaceutical network industry] in recent years, the state's supervision on the purchase and sale of medical equipment has been upgraded, which can be described as a multi pronged approach, with frequent emergence of powerful drugs In recent days, the special research established for the regulatory measures of drug procurement in public hospitals is a big move for the whole industry   On December 6, the special research on "special research on the construction of integrity system and punishment system in drug procurement of public hospitals" was launched at the small-scale meeting of the state health insurance bureau, including the China Pharmaceutical Enterprise Management Association, China Association of traditional Chinese medicine, China Chemical Industry Association and China Association of foreign funded enterprises pharmaceutical research and development industry committee (rdpac) And other relevant people participated in the discussion It is reported that the special research will be completed within two months During this period, the research team will complete the investigation and interview with the representatives of relevant government departments, industry associations, enterprises and hospitals, as well as a series of data collection This may indicate that in the future, nationwide, the state health insurance bureau will establish two major systems, namely, integrity evaluation system and punishment system, to conduct industry supervision on the drug procurement of public hospitals, and curb "sales with money" Punishment has always been an important way to prevent drug kickback, but at present, there are some problems in the punishment of drug kickback, such as the separation of terms and the separation of policies, with limited effect In addition, most of the punishment measures in China are aimed at doctors, that is to say, the object of "sales with gold" All of these problems make the role of punishment very limited, so the research team, relying on the source of cases such as the judgment document network, tries to establish a set of credit evaluation system for pharmaceutical production enterprises, and based on the system, to punish the dishonest enterprises in different levels, so as to better regulate the behavior of relevant parties and promote industry self-discipline According to the person in charge of the research, the credit evaluation system for pharmaceutical manufacturers will have two major functions: one can be used for publicity and dissemination, such as regularly publishing the national enterprise credit ranking, list of dishonest behaviors, etc.; the other can be used for public retrieval and viewing of enterprise credit records According to this evaluation system, the dishonest enterprises can also be punished at different levels, such as reducing the purchase price, banning market entry, etc "We plan to establish an independent investigation and punishment system, and the medical insurance department can directly punish the dishonest enterprises." In fact, the rumors about drug kickbacks have not really disappeared in recent years, and the state's supervision of drug kickbacks has also been in a state of continuous strengthening As early as 2017, the former State Food and Drug Administration and the former state health and Family Planning Commission issued the measures for the administration of registration and filing of medical representatives (Trial) (Draft for comments), requiring that doctors should not be misled to use drugs, etc But such methods only touch the surface As for how to eliminate the "sales with gold" fundamentally, it still needs the combination of special actions and conventional methods, so there is the research on the above-mentioned integrity evaluation and dishonesty punishment system In June this year, the Ministry of finance, together with the medical insurance bureau, carried out an account check on 77 pharmaceutical enterprises, covering six subdivisions: chemical pharmacy, biological products, medical devices, medical services, pharmaceutical commerce and traditional Chinese medicine preparations Among them, the authenticity of sales expenses is the focus of inspection In July, Jiangsu Provincial Health and Health Commission also issued the measures for the management of bad records of commercial bribery in the field of pharmaceutical purchase and sale, which stipulates that pharmaceutical circulation enterprises, which are found to have bad records for the first time, or two or more times within five years, and their agents, will be kicked out of the provincial market for two years Generally speaking, the state has strict requirements on the purchase behavior of public hospitals, but because the hospital itself can not effectively avoid kickbacks, only the purchase frequency has been reduced In the future, it has always been the credit punishment system of drug kickback behavior, or it will become a key to optimize the supervision of hospitals, and promote the development of hospital management to be more reasonable and efficient.